ARCAGY-GINECO
The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.
GINECO was founded in 1993 as France's cooperative group for ovarian, endometrial, cervical and rare gynaecologic cancers, with ARCAGY as its academic sponsor and research organisation. As a founding member of the European ENGOT network and the Gynecologic Cancer InterGroup, it led PAOLA-1/ENGOT-ov25, which showed olaparib plus bevacizumab maintenance improves progression-free and, in HRD-positive disease, overall survival in newly diagnosed ovarian cancer. GINECO also ran the CHIVA and ICON7 contributions, elderly-specific ovarian trials and the rare-tumour TMRG network, and it co-develops immunotherapy trials in endometrial and cervical cancer with the GOG Foundation.
- PAOLA-1 (olaparib plus bevacizumab)
- Elderly ovarian cancer trials
- ENGOT and GCIG leadership
- Rare gynaecologic tumours network
Pages like this
not linked directly; found by shared links- InstitutionSociety of Gynecologic Oncology
Shares PAOLA-1 / ENGOT-ov25, European Society of Gynaecological Oncology, HRD & BRCA testing, GOG Foundation.
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), PARP inhibitors, Olaparib.
- PairingPARP inhibitor + bevacizumab maintenance (HRD-positive)
Shares PAOLA-1 / ENGOT-ov25, Homologous recombination deficiency (HRD), Olaparib, Ovarian cancer.
- Key paperPAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), Anti-angiogenic therapy, PARP inhibitors.
- PersonAmit M. Oza
Shares Niraparib, Olaparib, Endometrial cancer, Ovarian cancer.
- InstitutionStephenson Cancer Center, OU Health
Shares PARP inhibitors, Olaparib, Endometrial cancer, Cervical cancer.
- IdeactDNA-guided duration of PARP maintenance
Shares Niraparib, PARP inhibitors, Olaparib, Ovarian cancer.
- PersonGiovanni Scambia
Shares European Society of Gynaecological Oncology, Endometrial cancer, Cervical cancer, Ovarian cancer.